Filtered By:
Drug: SGLT2 Inhibitors

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 230 results found since Jan 2013.

Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?
We have read with great interest a study of meta-analysis1 recently published in Journal of Stroke and Cerebrovascular Diseases. In that study1 Barkas and colleagues drew their main conclusion that sodium-glucose transporter 2 (SGLT2) inhibitors reduce the risk of total stroke in patients with type 2 diabetes mellitus (T2DM) and impaired renal function (IRF), which was based on the result of meta-analysis on the outcome of total stroke (including ischemic and hemorrhagic stroke) in the subgroup of patients with T2DM and IRF (Fig.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2021 Category: Neurology Authors: Li-Min Zhao, Liang-Liang Ding, Ze-Lin Zhan, Mei Qiu Tags: Letter to the Editor Source Type: research

Risk of New-onset Stroke in Patients with Type 2 Diabetes with Chronic Kidney Disease on Sodium-glucose Co-transporter-2 Inhibitor Users
This study aimed to examine the association between the use of SGLT2 inhibitors and NOS risk in patients with T2D and CKD. We conducted a nationwide retrospective cohort study using data from the Taiwan Health Insurance Review and Assessment Service database for the years 2004 to 2019. The primary outcome was the risk of incident stroke, which was estimated using hazard ratios (HRs) and 95% confidence intervals (CIs). We used multiple Cox regression modeling to analyze the association between SGLT2 inhibitor use and the risk of stroke in patients with T2D and CKD. In a cohort of 113,710 patients with T2D and CKD who were u...
Source: Translational Stroke Research - July 14, 2023 Category: Neurology Source Type: research

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Abstract Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both m...
Source: Diabetes and Metabolism - May 15, 2017 Category: Endocrinology Authors: Bonnet F, Scheen AJ Tags: Diabetes Metab Source Type: research

Subtype-Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study.
Abstract Volume depletion as an adverse events (AE) caused by sodium-glucose cotransporter-2 inhibitors (SGLT2i) because of their diuretic effect may raise the concern about the risk of lacunar stroke; however, an earlier meta-analysis reported no significant increase in the incidence of stroke without clearly distinguishing stroke subtypes. Here, aiming to investigate subtype-wise reporting of stroke potentially related to SGLT2i treatment, we conducted a disproportionality analysis using the Japanese Adverse Drug Event Report database, which contains approximately 500 000 cases recorded between April 2004 and M...
Source: The Journal of Clinical Pharmacology - December 1, 2019 Category: Drugs & Pharmacology Authors: Sato K, Mano T, Iwata A, Toda T Tags: J Clin Pharmacol Source Type: research

Reducing Ischemic Stroke in Diabetes: The Role of GLP-1 RAs
J Fam Pract. 2023 Jul;72(6 Suppl):S55-S60. doi: 10.12788/jfp.0624.ABSTRACTStroke is a significant cause of mortality worldwide, and diabetes is an independent risk factor for ischemic stroke occurrence and recurrence. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower the risk of ischemic stroke through beneficial effects on traditional stroke risk factors such as hyperglycemia, hypertension, and dyslipidemia. Primary care practitioners (PCPs) can play a substantial role in reducing ischemic stroke; studies have indicated that patients who have a PCP at the time of first stroke have a lower risk of stroke recurren...
Source: The Journal of Family Practice - August 7, 2023 Category: Practice Management Authors: John E Anderson Javed Butler Andrei V Alexandrov Source Type: research